Abciximab dosage and administration: Difference between revisions

Revision as of 19:52, 29 January 2014

Adapted from the FDA Package Insert.

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{SS}}, {{PB}}
-==Indications and Usage==
-Abciximab is indicated as an adjunct to [[percutaneous coronary intervention]] for the prevention of cardiac ischemic complications.
-* In patients undergoing [[percutaneous coronary intervention]]
+<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher =  | date =  | accessdate = }}</ref>
-* In patients with [[unstable angina]] not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
-Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.
-Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher =  | date =  | accessdate = }}</ref>
 ==References==